Saxagliptin
- Generic Name
- Saxagliptin
- Brand Names
- Kombiglyze, Komboglyze, Onglyza, Qtern, Qternmet
- Drug Type
- Small Molecule
- Chemical Formula
- C18H25N3O2
- CAS Number
- 361442-04-8
- Unique Ingredient Identifier
- 8I7IO46IVQ
- Background
Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
- Indication
Treatment of type 2 diabetes mellitus to improve glycemic control in combination with other agents or as monotherapy.
- Associated Conditions
- Type 2 Diabetes Mellitus
Bioequivalence Study Coadministered to Healthy Subjects in the Fasted State
- First Posted Date
- 2014-08-22
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT02223065
Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 72
- Registration Number
- NCT02182895
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Cystic Fibrosis Related Diabetes
- First Posted Date
- 2014-05-29
- Last Posted Date
- 2014-05-29
- Lead Sponsor
- Ram Weiss
- Target Recruit Count
- 30
- Registration Number
- NCT02148978
- Locations
- 🇮🇱
Hadassah Har Hazofim, Jerusalem, Israel
Effects of Antidiabetic Medications on the Postprandial State in Prediabetes
- Conditions
- PrediabetesObesity
- Interventions
- First Posted Date
- 2014-04-04
- Last Posted Date
- 2018-07-03
- Target Recruit Count
- 21
- Registration Number
- NCT02104739
- Locations
- 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States
Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2014-04-04
- Last Posted Date
- 2017-10-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 953
- Registration Number
- NCT02104804
- Locations
- 🇨🇳
Research Site, Shiyan, China
DPP-4 Inhibition, Incretins and Islet Function
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2014-03-17
- Last Posted Date
- 2017-08-23
- Lead Sponsor
- Lund University
- Target Recruit Count
- 24
- Registration Number
- NCT02089438
- Locations
- 🇸🇪
Clinical Research Department, Lund, Sweden
Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2015-06-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 72
- Registration Number
- NCT02060201
Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients
- First Posted Date
- 2013-12-31
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- George Washington University
- Target Recruit Count
- 42
- Registration Number
- NCT02024477
- Locations
- 🇺🇸
Medical Faculty Associates Inc, Washington, District of Columbia, United States
Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis
- Conditions
- Disorder of Glucose RegulationPolycystic Ovary Syndrome
- Interventions
- First Posted Date
- 2013-12-27
- Last Posted Date
- 2017-06-28
- Lead Sponsor
- Woman's
- Target Recruit Count
- 38
- Registration Number
- NCT02022007
- Locations
- 🇺🇸
Woman's Hospital, Baton Rouge, Louisiana, United States
Effect of Saxagliptin on Pre-Diabetes Mellitus and Obesity
- Conditions
- Prediabetes
- Interventions
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Shandong Provincial Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT01960205
- Locations
- 🇨🇳
Shandong Provincial Hospital, Jinan, Shandong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.